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Background: Despite its autosomal dominant inheritance, sex impacts the prevalence and phenotype of clinically apparent hypertrophic 
cardiomyopathy (HCM). However, the effect of sex in genotested HCM patients is not well understood. We sought to investigate the relationship 
between sex with clinical and transthoracic echocardiography (TTE) measures in an HCM cohort who underwent genetic testing.
methods: Clinical and TTE measures were collected in 500 consecutive patients who underwent genetic testing at a tertiary referral center from 
2005 to 2010. Baseline clinical and TTE characteristics in men and women were compared among the genotested cohort and a subgroup of 
genopositive HCM subjects (n=179, patients with an identified pathogenic HCM gene mutation).
results: There was a greater prevalence of men within our genotested cohort (65%, p< 0.0001). Women were older at diagnosis (47±1 vs. 43±1 
years, p=0.019), more likely to have a positive genotype (45±4 vs. 30±3%, p=0.0008), and to present with a higher NYHA class upon referral 
(1.9±0.06 vs. 1.6±0.04, p< 0.0001). Additionally, women were more likely to have a family history of HCM (43±4 vs. 32±3%, p=0.013) and sudden 
cardiac death (16±3 vs. 9±2%, p=0.048). Women also had higher estimated left atrial pressures (14±0.5 vs. 12±0.4 mmHg, p=0.0003), higher right 
ventricular systolic pressures (35±0.7 vs. 32±0.5 mmHg, p=0.0008), and greater indexed maximal wall thickness and left ventricular end diastolic 
dimension (LVEDD) (11±0.2 vs. 10±0.2 mm/m2 and 24±0.3 vs. 22±0.2 mm/m2, respectively, p< 0.0001). Among the genopositive HCM subgroup, 
which had no significant difference in sex prevalence (male 55%, p=0.13), nearly all these findings were attenuated, with the exception of higher 
NYHA class (1.9±0.01 vs. 1.6±0.01, p=0.015) and indexed LVEDD (25±0.4 vs. 22±0.4 mm/m2, p=0.0002) in women.
conclusions:  Female sex is associated with adverse clinical and TTE measures within our genotested cohort, which is predominantly driven by 
genonegative HCM patients and attenuated within the genopositive HCM subgroup. Whether these sex differences are due to biology, referral bias, or 
true genetic HCM remain to be clarified.
